HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Dermatofibrosarcoma protuberans — Clinical Guidelines

Overview

Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive fibroblastic tumor of the skin with low metastatic potential but high recurrence rates if incompletely resected 1 5.

Diagnosis

Clinical suspicion based on characteristic growth patterns

Histopathological confirmation essential; biopsy required 1 5

Chromosomal translocations (e.g., t(17;22)) and fusion gene transcripts (e.g., EWSR1-NR4A3) aid in diagnosis 1

Misdiagnosis common, often mistaken for benign lesions 2

Management

Primary treatment: Complete surgical excision with adequate margins

- Microscopically controlled surgery recommended to minimize recurrence 1 4 - Standard excision with lateral margins of 2-3 cm acceptable if microscopic control unavailable 1

Adjunctive therapy:

- Imatinib: Approved for advanced or metastatic DFSP; objective response rates ~50% 5 6 - Radiation therapy for inoperable or metastatic cases 5

Special Populations

Pregnancy: No specific guidelines provided in abstracts 7 8 9 10

Pediatrics: No specific data provided in abstracts 7 8 9 10

Elderly: No specific considerations noted in abstracts 7 8 9 10

Comorbidities: Management similar regardless of comorbidities; focus on complete resection 1 5

Key Recommendations

Surgical excision with margins ≥3 cm significantly reduces recurrence rates (Evidence: Strong 4)

Microscopically controlled surgery is preferred to ensure complete tumor removal (Evidence: Moderate 1)

Imatinib should be considered for advanced or metastatic DFSP cases (Evidence: Moderate 5 6)

Early dermatology consultation improves appropriate diagnosis and treatment outcomes (Evidence: Moderate 2)

Continuous cervical erector spinae plane block can be effective for perioperative analgesia in extensive DFSP surgeries (Evidence: Weak 3)

References

1 Saiag P, Lebbe C, Brochez L, Emile JF, Forsea AM, Harwood C et al.. Diagnosis and treatment of dermatofibrosarcoma protuberans. European interdisciplinary guideline - update 2024. European journal of cancer (Oxford, England : 1990) 2025. link 2 Kelly JH, Christensen L, Frohm ML. Impact of Dermatology Access on Dermatofibrosarcoma Protuberans Outcomes: A Retrospective Study in a Larger Cohort. South Dakota medicine : the journal of the South Dakota State Medical Association 2025. link 3 Mahendru K, Gupta N, Rangarajan K, Kumar S, Chandrashekhara SH. Cervical Erector Spinae Plane Block for Giant Dermatofibrosarcoma Protuberans of Neck and Chest Wall: A Case Report. AANA journal 2023. link 4 Chen Y, Jiang G. Association between surgical excision margins and outcomes in patients with dermatofibrosarcoma protuberans: A meta-analysis. Dermatologic therapy 2021. link 5 Ugurel S, Kortmann RD, Mohr P, Mentzel T, Garbe C, Breuninger H et al.. S1 guidelines for dermatofibrosarcoma protuberans (DFSP) - update 2018. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2019. link 6 Ugurel S, Becker JC. Imatinib in Dermatofibrosarcoma: Targeted Therapy or Immunotherapy?. The Journal of investigative dermatology 2017. link 7 Resnik KS, DiLeonardo M, Hunter CJ. Pedunculated presentation of dermatofibrosarcoma protuberans. Journal of the American Academy of Dermatology 2003. link00439-0) 8 Sinha VD, Dharker SR, Kalra GS. Dermatofibrosarcoma protuberans of scalp : a case report. Neurology India 2001. link 9 Agress R, Figge DC, Tamimi H, Greer B. Dermatofibrosarcoma protuberans of the vulva. Gynecologic oncology 1983. link90104-x) 10 Jacyk WK, Pasnikowski T. Dermatofibrosarcoma of the face. Report of two cases from Nigeria. Dermatologica 1977. link

Dermatofibrosarcoma protuberans